SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending downwards following its earnings report, with concerns primarily focused on increased capital expenditures and debt related to AI infrastructure. Despite strong earnings, the community is discussing the company's future ability to monetize AI investments given these financial obligations. Some view the sell-off as an overreaction and a buying opportunity, while others express fears of an AI bubble.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to its low float and upcoming conference, where the company may share updates on its shift towards AI and high-performance computing. Community members are discussing potential short squeezes and high price targets, fueled by the company's expanding infrastructure and possible new contracts. Sentiment remains volatile, with traders closely monitoring key price levels and potential catalysts.

Black Titan Corp. was formed for the purpose of effecting a merger between Titan Pharmaceuticals Inc. and TalenTec Sdn Bhd. It intends to explore and identify viable business opportunities. The company was founded on July 11, 2024 and is headquartered in Petaling Jaya, Malaysia.

Black Titan Corp.

BTTC is trending due to its recent DAT+ risk management announcement, sparking high trading volume and volatile price action. Community discussions revolve around the potential for a short squeeze, comparisons to other stocks with similar setups, and caution due to the lack of concrete financial details in the news.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending as it approaches inclusion in the S&P 500, fueling discussions around its valuation and potential for continued gains, with some community members expressing skepticism, citing weak fundamentals, while others point to a potential short squeeze driven by high short interest and call option activity.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

TTD is trending as investors debate whether the stock's significant YTD decline represents a buying opportunity or reflects deeper concerns about competition and market share, particularly with Amazon. Community discussions revolve around potential overselling due to tax-loss harvesting, the company's fundamentals (cash, buybacks), and the CEO's performance amidst the stock's poor performance, with some suggesting leadership changes while others point to potential for a rebound in 2026 due to political ad spend.

AXIL Brands, Inc. engages in the manufacture, market, sale and distribution of hearing and audio enhancement, and protection products. It operates through the Hearing Enhancement and Protection, and Hair Care and Skin Care segments. The Hearing Enhancement and Protection segment includes ear buds, earmuffs, ear plugs, outdoor speakers, and ear care items. The Hair Care and Skin Care segment focuses on expanding its business-to-business salon sales through its network of domestic and international distributors. The company was founded on May 21, 2015 and is headquartered in Beverly Hills, CA.

AXIL Brands Inc.

AXIL Brands is trending due to news of a national retail distribution agreement with Walmart, sparking excitement about increased market reach. Community discussions revolve around the potential for a short squeeze, given the stock's high short interest and relatively small float. Some traders are also monitoring JZXN, drawing comparisons to TGL, while others express skepticism, suggesting the hype may be overblown and the price could decline.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending as investors discuss its potential in treating cancers, particularly after positive data in prostate cancer trials, while also citing undervaluation. The community is actively discussing the possibility of a short squeeze given the high short interest. Some also speculate about potential partnerships and acquisitions in the near future, especially with a key presentation approaching.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe ($ADBE) is trending as analysts debate whether strong Q4 earnings and AI integration are enough to offset concerns about 2026 guidance and competition from firms like Figma. The community is discussing recent price target adjustments and whether the stock is currently undervalued, presenting a buying opportunity, or if it's a value trap due to broader market sentiment.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to a recent debt refinancing announcement, sparking mixed reactions within the community. While some view the move as a strategic advantage for potential buyout negotiations and extended financial flexibility, others express concerns about higher interest rates and management's financial decisions. Community members are actively debating the implications of the refinancing on the company's future and potential acquisition prospects.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending following strong Q3 earnings, optimistic revenue guidance, and an announced contract with the U.S. Navy, driving community excitement. Wedbush recently updated its rating for Planet Labs to Outperform, setting a target of $17. Investors are closely watching for a potential breakout above its 52-week high, with some anticipating a significant rally.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal

Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook. 

<ul class="summary-bullets"><li>As part of the agreement, the U.K. government will lift the threshold used by the NHS to determine if a drug is cost-effective by 25%.</li><li>It has also agreed to a reduction in the industry sales rebate on NHS drug prices to 15% in 2026 from the nearly 23% currently.</li></ul>The United States and the United Kingdom have reached an in-principle agreement on a zero-tariff deal on pharmaceuticals.According to the agreement’s details announced by the Office of the United States Trade Representative, the deal will result in zero tariffs on pharmaceutical products imported in the U.S. from the U.K. It will also lead to an increase in the U.K. government’s spending on the National Health Service (NHS).The agreement between the U.S. and U.K. on pharmaceutical pricing will remain in effect until the end of President Donald Trump’s term in 2029.In exchange, the U.K. government has agreed to a reduction in the industry sales rebate on NHS drug prices to 15% in 2026 from the nearly 23% currently, and remain at that level or below until 2029.<a href="https://stocktwits.com/symbol/AZN">AstraZeneca Plc.’s</a> (AZN) shares were flat in Monday’s opening trade. Retail sentiment around the company trended in the ‘bullish’ territory at the time of writing. AstraZeneca is the U.K.’s largest pharmaceutical company.<h2 class="st-heading-2">Increase In NHS Spending</h2>As part of the agreement, the U.K. government will also lift the threshold used by the NHS to determine if a drug is cost-effective by 25%.“Today’s agreement is a major win for American workers and our innovation economy. We are strengthening supply chains, creating high-quality jobs, and reinforcing America as the world’s premier hub for life-sciences investment,” said Secretary Howard Lutnick.<h2 class="st-heading-2">US-UK Trade Deal</h2>President Trump&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-unveils-us-uk-trade-deal-with-boost-for-steel-agriculture-boeing/chifoL4RbkK">unveiled</a> the U.S.-U.K. trade deal in July, stating that it will open up billions of dollars in market access for exports from the United States. This also included a $10 billion aircraft sale involving Boeing Co. (BA).“With this deal, the U.K. joins the U.S. in affirming that reciprocity and fairness is an essential and vital principle of international trade,” President Trump said following the announcement in July.The deal eased restrictions on exports of beef, ethanol, chemicals, machinery, and other industrial products.&nbsp;<a href="https://stocktwits.com/symbol/AZN">AZN stock</a> is up 41% year-to-date and 37% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/michael-burry-tesla-ridiculously-over-valued-elon-musk/cLI7OPvREie">Michael Burry Takes Aim At Musk’s Tesla Again, Says TSLA Stock Is Still ‘Ridiculously Overvalued’: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

UK Prime Minister Sir Keir Starmer meets with U.S. President Donald Trump, during a bilateral meeting in the Oval Office at the White House

US, UK Reach In-Principle Agreement On Zero-Tariffs On Pharmaceuticals

The agreement between the U.S. and U.K. on pharmaceutical pricing will remain in effect until the end of President Donald Trump’s term in 2029.

Equity

Pharma ETFs in Spotlight Following Robust Q3 Earnings Results

Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Does Trump's MFN Policy Put Pharma ETFs in the Crosshairs?

With Trump's MFN policy cutting U.S. drug prices, will Pharma ETFs such as IHE, heavily weighted toward Eli Lilly and Novo Nordisk, lose momentum?


Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

4 Reasons to Buy Pharma ETFs Now for a Healthy Portfolio

Pharma's Trump-Pfizer boost sparks momentum, making ETFs PPH, IHE, PJP & XPH attractive for defensive, undervalued growth plays.

White House Press Secretary Karoline Leavitt said on Thursday that President Donald Trump is set to send out letters to 17 pharmaceutical company CEOs in the U.S., including Eli Lilly (LLY), giving them 60 days to address the global pricing disparity of drugs.“Other nations have been free-loading on U.S. innovation for far too long, and it is time they pay their fair share,” said Leavitt, reading out one of the letters, addressed to Eli Lilly CEO David A. Ricks.<a href="http://stocktwits.com/symbol/LLY">Eli Lilly’s stock</a> dipped more than 1% in afternoon trade after the news broke. On Stocktwits, retail sentiment around the pharmaceutical giant remained in ‘bullish’ territory over the past day.Other pharma stocks also took a hit. Moderna (MRNA) extended its downtrend, dipping nearly 7%, AstraZeneca (AZN) slipped more than 3% and Pfizer (PFE) was down over 1%.&nbsp;The warning comes after Trump signed an executive order delivering ‘most favored nation’ prescription drug pricing for U.S. patients in May.The letter alleges that most of the proposals that the Trump administration has received to resolve the issue of drug pricing promised “more of the same, shifting blame, and requesting policy changes that would result in billions of dollars in handouts to the industry.”It outlines that drug makers have 60 days to achieve the following goals:- Extend the ‘most favored nation’ pricing to Medicaid- Guarantee ‘most favored nation’ pricing for newly launched drugs- Return increased revenues abroad to American patients and taxpayers- Provided for direct purchasing at ‘most favored nation’ pricing“But if you refuse to step up, we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices,” warned the letter, adding that the Trump administration, U.S. Health Secretary Robert Kennedy Jr. and Centers for Medicare and Medicaid Services (CMS) administrator Mehmet Oz stand ready to implement these terms.&nbsp;According to the letter, the companies have till September 29 to comply.&nbsp;The VanEck Pharmaceutical ETF (PPH) dropped more than 2%, while the iShares U.S. Pharmaceutics ETF (IHE) edged 0.8% lower.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sec-chair-unveils-project-crypto-to-back-trump-push-for-us-crypto-dominance/choLhyMRdG4">SEC Chair Unveils ‘Project Crypto’ To Back Trump’s Push For US Crypto Dominance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Donald Trump gestures during a meeting with British Prime Minister Keir Starmer (not pictured) on July 28, 2025 in Turnberry, Scotland. (Photo by Christopher Furlong/Getty Images)

Trump To Issue 60-Day Warning Letters To Drugmakers Over Pricing 

The U.S. President is expected to send out these letters through his social media platform, Truth Social.

Invesco Capital Management LLC - Invesco Pharmaceuticals ETF

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

Current Price	$105.14
Prev Close	$105.12
Open	$105.42
Dividend Yield	N/A
50-Day Moving Average	$98.95
Beta	N/A
Avg. Volume	16,886.58
PE Ratio	N/A

52-Week High	$106.75
52-Week Low	$72.25
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

PJP
Invesco Dynamic Pharmaceuticals ETF

Feed

News

Sentiment

Fundamentals

Info

Latest PJP News

PJPInvesco Dynamic Pharmaceuticals ETF